Agios Pharm (AGIO)vsargenx NV ADR (ARGX)
AGIO
Agios Pharm
$38.12
+0.24%
HEALTHCARE · Cap: $1.87B
ARGX
argenx NV ADR
$891.76
+1.05%
HEALTHCARE · Cap: $54.94B
Smart Verdict
WallStSmart Research — data-driven comparison
argenx NV ADR generates 5915% more annual revenue ($5.92B vs $98.34M). ARGX leads profitability with a 31.7% profit margin vs 0.0%. ARGX earns a higher WallStSmart Score of 73/100 (B).
AGIO
Hold38
out of 100
Grade: F
ARGX
Strong Buy73
out of 100
Grade: B
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+71.4%
Fair Value
$97.03
Current Price
$38.12
$58.91 discount
Margin of Safety
+67.5%
Fair Value
$2566.94
Current Price
$891.76
$1675.18 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 259.3% year-over-year
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Reasonable price relative to book value
Every $100 of equity generates 31 in profit
Keeps 32 of every $100 in revenue as profit
Strong operational efficiency at 36.3%
Revenue surging 52.1% year-over-year
Earnings expanding 50.6% YoY
Conservative balance sheet, low leverage
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Weak financial health signals
Premium valuation, high expectations priced in
Weak financial health signals
Trading at 165.8x book value
Comparative Analysis Report
WallStSmart ResearchBull Case : AGIO
The strongest argument for AGIO centers on Revenue Growth, Debt/Equity, Altman Z-Score. Revenue growth of 259.3% demonstrates continued momentum.
Bull Case : ARGX
The strongest argument for ARGX centers on Return on Equity, Profit Margin, Operating Margin. Profitability is solid with margins at 31.7% and operating margin at 36.3%. Revenue growth of 52.1% demonstrates continued momentum.
Bear Case : AGIO
The primary concerns for AGIO are EPS Growth, Market Cap, Profit Margin.
Bear Case : ARGX
The primary concerns for ARGX are P/E Ratio, Piotroski F-Score, Price/Book.
Key Dynamics to Monitor
AGIO profiles as a hypergrowth stock while ARGX is a growth play — different risk/reward profiles.
AGIO carries more volatility with a beta of 0.63 — expect wider price swings.
AGIO is growing revenue faster at 259.3% — sustainability is the question.
ARGX generates stronger free cash flow (749M), providing more financial flexibility.
Bottom Line
ARGX scores higher overall (73/100 vs 38/100), backed by strong 31.7% margins and 52.1% revenue growth. AGIO offers better value entry with a 71.4% margin of safety. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Agios Pharm
HEALTHCARE · BIOTECHNOLOGY · USA
Agios Pharmaceuticals, Inc., a biopharmaceutical company, is dedicated to drug discovery and development in the field of cellular metabolism and adjacent areas of biology. The company is headquartered in Cambridge, Massachusetts.
Visit Website →argenx NV ADR
HEALTHCARE · BIOTECHNOLOGY · USA
argenx SE, a clinical-phase biotechnology company, focuses on the development of antibody-based therapies for the treatment of autoimmune diseases, hematology and cancer. The company is headquartered in Breda, the Netherlands.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?